1:
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams.
N Engl J Med. 2008 Jul 24;359(4):339-54.
PMID: 18650512 [PubMed - indexed for MEDLINE]
Related Articles
2:
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A.
J Infect Dis. 2008 Jul 1;198(1):23-30.
PMID: 18491970 [PubMed - indexed for MEDLINE]
Related Articles
3:
Insulin-like growth factor axis and oncogenic human papillomavirus natural history.
Harris TG, Burk RD, Yu H, Minkoff H, Massad LS, Watts DH, Zhong Y, Gange S, Kaplan RC, Anastos K, Levine AM, Moxley M, Xue X, Fazzari M, Palefsky JM, Strickler HD.
Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):245-8.
PMID: 18199731 [PubMed - indexed for MEDLINE]
Related Articles
9:
Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI.
AIDS. 2007 Sep 12;21(14):1957-63.
PMID: 17721103 [PubMed - indexed for MEDLINE]
Related Articles
11:
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team.
J Infect Dis. 2007 Jul 15;196(2):304-12. Epub 2007 Jun 5.
PMID: 17570119 [PubMed - indexed for MEDLINE]
Related Articles
12:
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C.
AIDS. 2007 Jun 19;21(10):1245-52.
PMID: 17545700 [PubMed - indexed for MEDLINE]
Related Articles
17:
Specific infections, infection-related behavior, and risk of non-Hodgkin lymphoma in adults.
Vajdic CM, Grulich AE, Kaldor JM, Fritschi L, Benke G, Hughes AM, Kricker A, Turner JJ, Milliken S, Armstrong BK.
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1102-8.
PMID: 16775166 [PubMed - indexed for MEDLINE]
Related Articles
18:
A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
Newton R, Carpenter L, Casabonne D, Beral V, Babiker A, Darbyshire J, Weller I, Weiss R, Kwan A, Bourboulia D, Munoz F, Lagos D, Boshoff C.
Br J Cancer. 2006 May 22;94(10):1504-9.
PMID: 16705315 [PubMed - indexed for MEDLINE]
Related Articles
20:
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C.
Blood. 2006 May 15;107(10):3832-40. Epub 2006 Jan 12.
PMID: 16410446 [PubMed - indexed for MEDLINE]
Related Articles